Fortress Biotech Inc.
http://www.fortressbiotech.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fortress Biotech Inc.
As 2024 Begins, US FDA’s Novel Agent Prospects Look A Lot Like 2023
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
Zydus On Acquisitions, $100m Specialty Biz Target, Asacol Competition
Zydus is still on the lookout for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of generic Revlimid sales in Q2 led to a 24% drop over the previous quarter.
Zydus On Acquisitions, $100m Specialty Biz Target, gAsacol Competition
Zydus is still on the look out for deals post the recent acquisition of UK-based LiqMeds group as it sets a $100m sales target from specialty/rare disease products. Meanwhile, US revenues are seen stabilizing with new launches, even as lack of Revlimid sales in Q2 led to a 24% drop over the previous quarter.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aevitas Therapeutics, Inc.
- Altamira Bio
- Avenue Therapeutics, Inc. (ATXI)
- Baergic Bio, Inc.
- Caelum Biosciences Inc.
- Cellvation, Inc.
- Checkpoint Therapeutics, Inc.
- Coronado Biosciences, Inc. (CNDO)
- Cyprium Therapeutics, Inc.
- DiaVax Biosciences
- Helocyte, Inc.
- Journey Medical Corporation (JMC)
- Mustang Bio, Inc.
- Mustang Therapeutics, Inc. (MBIO)
- National Holdings Corporation
- Oncogenuity, Inc.
- Tamid Bio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice